A detailed history of Exodus Point Capital Management, LP transactions in Puma Biotechnology, Inc. stock. As of the latest transaction made, Exodus Point Capital Management, LP holds 30,905 shares of PBYI stock, worth $93,333. This represents 0.0% of its overall portfolio holdings.

Number of Shares
30,905
Holding current value
$93,333
% of portfolio
0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$2.25 - $4.03 $69,536 - $124,547
30,905 New
30,905 $79,000
Q1 2024

May 14, 2024

BUY
$4.29 - $7.4 $67,039 - $115,639
15,627 New
15,627 $83,000
Q2 2022

Aug 19, 2022

SELL
$1.64 - $3.3 $16,526 - $33,254
-10,077 Closed
0 $0
Q1 2022

May 13, 2022

SELL
$2.13 - $3.24 $199,960 - $304,164
-93,878 Reduced 90.31%
10,077 $29,000
Q4 2021

Feb 11, 2022

SELL
$2.85 - $6.58 $30,101 - $69,497
-10,562 Reduced 9.22%
103,955 $316,000
Q3 2021

Nov 15, 2021

BUY
$6.63 - $9.39 $491,853 - $696,606
74,186 Added 183.94%
114,517 $803,000
Q2 2021

Aug 16, 2021

SELL
$8.98 - $11.6 $167,198 - $215,980
-18,619 Reduced 31.58%
40,331 $370,000
Q1 2021

May 17, 2021

BUY
$9.38 - $13.63 $266,851 - $387,759
28,449 Added 93.27%
58,950 $573,000
Q4 2020

Feb 16, 2021

SELL
$7.78 - $12.13 $59,446 - $92,685
-7,641 Reduced 20.03%
30,501 $313,000
Q3 2020

Nov 16, 2020

BUY
$9.5 - $11.14 $55,907 - $65,558
5,885 Added 18.24%
38,142 $385,000
Q2 2020

Aug 14, 2020

BUY
$7.01 - $13.24 $226,121 - $427,082
32,257 New
32,257 $336,000
Q4 2019

Feb 14, 2020

SELL
$6.5 - $10.73 $214,870 - $354,701
-33,057 Closed
0 $0
Q3 2019

Nov 14, 2019

BUY
$8.75 - $12.85 $289,248 - $424,782
33,057 New
33,057 $356,000

Others Institutions Holding PBYI

About PUMA BIOTECHNOLOGY, INC.


  • Ticker PBYI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,556,000
  • Market Cap $138M
  • Description
  • Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...
More about PBYI
Track This Portfolio

Track Exodus Point Capital Management, LP Portfolio

Follow Exodus Point Capital Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Exodus Point Capital Management, LP with notifications on news.